Aug 2 (Reuters) - Medical device company CryoCor Inc. said the U.S. Food and Drug Administration has granted pre-market approval for its device for the treatment of right atrial flutter, or abnormal ...

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights ...

Value stream management involves people in the organization to examine workflows and other processes to ensure they are deriving the maximum value from their efforts while eliminating waste — of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Tempus announced the FDA has granted a ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, ...

Samsung is working to make it possible for developers to create apps for Galaxy Watch, Smart TVs, and more Tizen devices with Google’s Flutter SDK. Flutter, Google’s massive cross-platform app ...

WASHINGTON, June 27 (Reuters) - A U.S. advisory panel backed an experimental CryoCor Inc. device to treat a type of abnormal heart rhythm, a Food and Drug Administration spokeswoman said on Wednesday.

Heartbeam Inc.'s algorithms performed as well on a standard 12-lead electrocardiography (ECG) as on its 3D ECG system in the detection of atrial fibrillation, atrial flutter and sinus rhythm, based on ...